Update on implications and mechanisms of angiogenesis in liver fibrosis

Hepatology Research

Volumn 45, Issue 2, 2015, Pages 162-178

  Zhang, Zili ^a   Zhang, Feng ^a   Lu, Yin ^a   Zheng, Shizhong ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Angiogenesis; Endothelial cells; Hepatic stellate cells; Liver fibrosis

Indexed keywords

ANGIOGENESIS; CHRONIC LIVER DISEASE; EXTRACELLULAR MATRIX; FIBROGENESIS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER NODULE; LIVER SINUSOID; NONHUMAN; PATHOGENESIS; PERICYTE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TISSUE REPAIR;

EID: 84921522307     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12415     Document Type: Review

References (147)

1. Hernandez-Gea V, Friedman SL. Pathogenesis of liver fibrosis. Annu Rev Pathol 2011; 6: 425-456.
2. Friedman SL. Mechanisms of fibrogenesis. Gastroenterology 2008; 134: 1655-1669.
3. Friedman SL. Evolving challenges in fibrosis. Nat Rev Gastroenterol Hepatol 2010; 7: 425-436.
4. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50: 1294-1306.
5. Rustgi VK, Davis GL, Herrine SK etal. Future trends in hepatology: challenges and opportunities. Hepatology 2008; 48: 655-661.
6. Kong D, Zhang F, Zhang Z etal. Clearance of activated stellate cells for fibrosis regression: molecular basis and translational potential. Biomed Pharmacother 2013; 67: 246-250.
7. Thabut D, Shah V. Intra angiogenesis and sinusoidal remodeling in chronic liver disease: new targets for the treatment of portal hypertension? J Hepatol 2010; 53: 976-980.
8. Valfre L, Novo E, Cannito S etal. Angiogenesis and liver fibrogenesis. Histol Histopathol 2009; 24: 1323-1341.
9. Coulon S, Heindryckx F, Geerts A etal. Angiogenesis in chronic liver disease and its complications. Liver Int 2011; 31: 146-162.
10. Mercedes F, David S, Jordi B etal. Angiogenesis in liver disease. J Hepatol 2009; 50: 604-620.
11. McLeod DS, Hasegawa T, Baba T etal. From blood islands to blood vessels: morphologic observations and expression of key molecules during hyaloid vascular system development. Invest Ophthalmol Vis Sci 2012; 53: 7912-7927.
12. Ranjit KG, Gordana V. Hypoxia, angiogenesis, and lung cancer. Goudar and Vlahovic 2008; 10: 277-282.
13. Moeller BJ, Richardson RA, Dewhirst MW. Hypoxia and radiotherapy: opportunities for improved outcomes in cancer treatment. Cancer Metastasis Rev 2007; 26: 241-248.
14. Ahn GO, Seita J, Hong BJ etal. Transcriptional activation of hypoxia-inducible factor-1 (HIF-1) in myeloid cells promotes angiogenesis through VEGF and S100A8. Proc Natl Acad Sci USA 2014; 111: 2698-2703.
15. Ndubuizu OI, Tsipis CP, Li A etal. Hypoxia-inducible factor-1 (HIF-1)-independent microvascular angiogenesis in the aged rat brain. Brain Res 2010; 1366: 101-109.
16. Fedele AO, Whitelaw ML, Peer DJ. Regulation of gene expression by the hypoxia-inducible factors. Mol Interv 2002; 2: 229-243.
17. Asahara T, Murohara T, Sullivan A etal. Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997; 275: 964-967.
18. Geenen IL, Molin DG, van den Akker NM etal. Endothelial cells (ECs) for vascular tissue engineering: venous ECs are less thrombogenic than arterial ECs. J Tissue Eng Regen Med 2012. doi: 10.1002/term.1642
19. Takakura N. Basic science of angiogenesis and its progress in clinical application. Rinsho Ketsueki 2008; 49: 1451-1459.
20. Carmeliet P, Jain RK. Molecular mechanisms and clinical applications of angiogenesis. Nature 2011; 473: 298-307.
21. Yan X. Tumor angiogenesis and molecular target therapy. Acta Biophysica Sinica 2010; 26: 180-193.
22. Francavilla C, Maddaluno L, Cavallaro U. The functional role of cell adhesion molecules in tumor angiogenesis. Semin Cancer Biol 2009; 19: 298-309.
23. Mayer G. Capillary rarefaction, hypoxia, VEGF and angiogenesis in chronic renal disease. Nephrol Dial Transplant 2011; 26: 1132-1137.
24. Greaves NS, Ashcroft KJ, Baguneid M etal. Current understanding of molecular and cellular mechanisms in fibroplasia and angiogenesis during acute wound healing. J Dermatol Sci 2013; 72: 206-217.
25. Greenberg JI, Shields DJ, Barillas SG etal. A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 2008; 456: 809-813.
26. Olivier R, Chantal H. Hypoxia: a link between fibrogenesis, angiogenesis, and carcinogenesis in liver disease. Semin Liver Dis 2010; 30: 258-270.
27. Ranjit KG, Gordana V. Hypoxia, angiogenesis, and lung cancer. Curr Oncol Rep 2008; 10: 277-282.
28. Moon JO, Welch TP, Gonzalez FJ, Copple BL. Reduced liver fibrosis in hypoxia-inducible factor-1alpha-deficient mice. Am J Physiol Gastrointest Liver Physiol 2009; 296: G582-592.
29. Lemos QT, Andrade ZA. Angiogenesis and experimental fibrosis. Mem Inst Oswaldo Cruz 2010; 105: 611-614.
30. Ribatti D, Nico B, Crivellato E. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55: 261-268.
31. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: a new function for the liver-specific pericyte? Hepatology 2007; 45: 817-825.
32. Domenico R, Beatrice N, Enrico C. The role of pericytes in angiogenesis. Int J Dev Biol 2011; 55: 261-268.
33. von Tell D, Armulik A, Betsholtz C. Pericytes and vascular stability. Exp Cell Res 2006; 312: 623-629.
34. Armulik A, Genove G, Betsholtz C. Pericytes: developmental, physiological, and pathological perspectives, problems, and promises. Dev Cell 2011; 21: 193-215.
35. Desiree V, Annika A, Christer B. Pericytes and vascular stability. Exp Cell Res 2006; 312: 623-629.
36. Hellerbrand C. Stellate cells-the pericytes in the liver. Pflugers Arch 2013; 465: 775-778.
37. Hajrasouliha AR, Sadrai Z, Chauhan SK etal. VEGF mimic provides potential strategy for blood vessel growth and ischemic tissue repair. Expert Rev Proteomics 2011; 8: 559-561.
38. Kimura H, Mochida S, Inao M etal. Angiopoietin/tie receptors system may play a role during reconstruction and capillarization of the sinusoids after partial hepatectomy and liver necrosis in rats. Hepatol Res 2004; 29: 51-59.
39. Raja R, Kale S, Thorat D etal. Hypoxia-driven osteopontin contributes to breast tumor growth through modulation of HIF1alpha-mediated VEGF-dependent angiogenesis. Oncogene 2014; 33: 2053-2064.
40. Blancher C, Moore JW, Talks KL etal. Relationship ofhypoxia-inducible factor(HIF)-1alpha and HIF-2alpha expression to vascular endothelial growth factorinduction and hypoxia survival in human breast cancer cell lines. Cancer Res 2000; 60: 7106-7113.
41. Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008; 22: 1276-1312.
42. Taura K, De Minicis S, Seki E etal. stellate cells secrete angiopoietin-1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738.
43. Vespasiani-Gentilucci U, Galati G, Mazzarelli C etal. Angiogenic cytokines in patients undergoing antiviral treatment for chronic hepatitis C virus infection. J Interferon Cytokine Res 2011; 31: 207-210.
44. Zhang ZL, Zhang JF, Yuan YF etal. Suppression of angiogenesis and tumor growth in vitro and in vivo using an anti-angiopoietin-2 single-chain antibody. Exp Ther Med 2014; 7: 543-552.
45. Wang R, Huebert RC, Shah VH. Sinusoidal endothelial cells coordinate liver regeneration and angiogenesisvia angiopoietin-2: an ode to prometheus. Gastroenterology 2014; 147: 533-534.
46. Hu J, Srivastava K, Wieland M etal. Endothelial cell-derived angiopoietin-2 controls liver regeneration as a spatiotemporal rheostat. Science 2014; 343: 416-419.
47. Zhao X, Guan JL. Focal adhesion kinase and its signaling pathways in cell migration and angiogenesis. Adv Drug Deliv Rev 2011; 63: 610-615.
48. Zhang F, Kong D, Lu Y, Zheng S. Peroxisome proliferator-activated receptor-gamma as a therapeutic target for fibrosis: from bench to bedside. Cell Mol Life Sci 2013; 70: 259-276.
49. Li L, Wang JY, Yang CQ, Jiang W. Effect of RhoA on transforming growth factor beta1-induced rat stellate cell migration. Liver Int 2012; 32: 1093-1102.
50. Pu KM, Sava P, Gonzalez AL. Microvascular targets for anti-fibrotic therapeutics. Yale J Biol Med 2013; 86: 537-554.
51. Stanculet N, Grigoraş A, Avadanei R etal. Relationship between Kuppfer cells, inflammation, and fibrosis in chronic hepatitis B and C. Rev Med Chir Soc Med Nat Iasi 2011; 117: 880-889.
52. Lade A, Noon LA, Friedman SL. Contributions of metabolic dysregulation and inflammation to nonalcoholic steatohepatitis, fibrosis, and cancer. Curr Opin Oncol 2014; 26: 100-107.
53. Talghini S, Shenasi A. Concomitant examination of inflammation and angiogenesis in the pathogenesis of primary moderate pterygium in a well-designed case-control study. Pak J Biol Sci 2013; 16: 1046-1050.
54. Kulkarni M, O'Loughlin A, Vazquez R. Use of a fibrin-based system for enhancing angiogenesis and modulating inflammation in the treatment of hyperglycemic wounds. Biomaterials 2014; 35: 2001-2010.
55. Nold-Petry CA, Rudloff I, Baumer Y etal. IL-32 promote angiogenesis. J Immunol 2014; 192: 589-602.
56. Nagasaki T, Hara M, Nakanishi H etal. Interleukin-6 released by colon cancer-associated fibroblasts is critical for tumour angiogenesis: anti-interleukin-6 receptor antibody suppressed angiogenesis and inhibited tumour-stroma interaction. Br J Cancer 2014; 110: 469-478.
57. Middleton K, Jones J, Lwin Z, Coward JI. Interleukin-6: an angiogenic target in solid tumours. Crit Rev Oncol Hematol 2014; 89: 129-139.
58. Tan PH, Chia SS, Toh SL etal. The dominant role of IL-8 as an angiogenic driver in a three-dimensional physiological tumor construct for drug testing. Tissue Eng Part A 2013; 20: 1758-1766.
59. Ehling J, Bartneck M, Wei X etal. CCL2-dependent infiltrating macrophages promote angiogenesis in progressive liver fibrosis. Gut 2014; 10: 1-12.
60. Tacke F. Functional role of intrahepatic monocyte subsets for the progressionof liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair 2012; 5: 27-35.
61. Naldini A, Carraro F. Role of inflammatory mediators in angiogenesis. Curr Drug Targets Inflamm Allergy 2005; 4: 3-8.
62. Koczy-Baron E, Kasperska-Zajac A. The role of vascular endothelial growth factor in inflammatory processes. Postepy Hig Med Dosw 2014; 68: 57-65.
63. Konisti S, Kiriakidis S, Paleolog EM. Hypoxia - a key regulator of angiogenesis andinflammation in rheumatoid arthritis. Nat Rev Rheumatol 2012; 8: 153-162.
64. Lerner-Natoli M. Inflammation, angiogenesis and epilepsy. Biol Aujourdhui 2011; 205: 33-41.
65. Sanz-Cameno P, Trapero-Marugán M, Chaparro M etal. Angiogenesis: from chronic liver inflammation to hepatocellular carcinoma. J Oncol 2010; 2010: 272170.
66. Wang J, Leclercq I, Brymora JM etal. Kupffer cells mediate leptin-induced liver fibrosis. Gastroenterology 2009; 137: 713-723.
67. Markovic N, McCaig LA, Stephen J etal. Mediators released from LPS-challenged lungs induce inflammatory responses in liver vascular endothelial cells and neutrophilic leukocytes. Am J Physiol Gastrointest Liver Physiol 2009; 297: G1066-1076.
68. Minutolo A, Conti B, Grelli S etal. Lymphocytes as liver damage mirror of HCV related adipogenesis deregulation. PLoS ONE 2014; 9: e92343.
69. Notas G, Kisseleva T, Brenner D. NK and NKT cells in liver injury and fibrosis. Clin Immunol 2009; 130: 16-26.
70. Heymann F, Trautwein C, Tacke F. Monocytes and macrophages as cellular targets in liver fibrosis. Inflamm Allergy Drug Targets 2009; 8: 307-318.
71. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011; 10: 509-516.
72. Tacke F. Functional role of intra monocyte subsets for the progression of liver inflammation and liver fibrosis in vivo. Fibrogenesis Tissue Repair 2012; 5: 27.
73. Liu C, Tao Q, Sun M etal. Kupffer cells are associated with apoptosis, inflammation and fibrotic effects in fibrosis in rats. Lab Invest 2010; 90: 1805-1816.
74. Bilzer M, Roggel F, Gerbes AL. Role of Kupffer cells in host defense and liver disease. Liver Int 2006; 26: 1175-1186.
75. Li H, Zheng HW, Chen H etal. Hepatitis B virus particles preferably induce Kupffer cells to produce TGF-β1 over pro-inflammatory cytokines. Dig Liver Dis 2012; 44: 328-333.
76. Kawaratani H, Tsujimoto T, Douhara A etal. The effect of inflammatory cytokines in alcoholic liver disease. Mediators Inflamm 2013; 2013: 495156.
77. Shuh M, Bohorquez H, Loss GE, Cohen AJ. Tumor necrosis factor-α: life and death of hepatocytes during liver ischemia/reperfusion injury. Ochsner J 2013; 13: 119-130.
78. Hironaka K, Sakaida I, Matsumura Y etal. Enhanced interstitial collagenase (matrix metalloproteinase-13) production of Kupffer cell by gadolinium chloride prevents pig serum-induced rat liver fibrosis. Biochem Biophys Res Commun 2000; 267: 290-295.
79. Baeck C, Wei X, Bartneck M etal. Pharmacological inhibition of the chemokine C-C motif chemokine ligand 2 (monocyte chemoattractant protein 1) accelerates liver fibrosis regression by suppressing Ly-6C+ macrophage infiltration in mice. Hepatology 2014; 59: 1060-1072.
80. Takahara Y, Takahashi M, Wagatsuma H etal. Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. World J Gastroenterol 2006; 12: 6473-6499.
81. Kocabayoglu P, Friedman SL. Cellular basis of fibrosis and its role in inflammation and cancer. Front Biosci 2013; 5: 217-230.
82. King KY, Goodell MA. Inflammatory modulation of HSCs: viewing the HSC as a foundation for the immune response. Nat Rev Immunol 2011; 11: 685-692.
83. Czaja AJ. Hepatic inflammation and progressive liver fibrosis in chronic liver disease. World J Gastroenterol 2014; 20: 2515-2532.
84. Hand P, Kowdley KV. Chemokines: potent mediators of hepatic inflammation and fibrosis in chronic liver diseases. Ann Hepatol 2013; 13: 152-154.
85. Tojima H, Kakizaki S, Kosone T etal. Hepatocyte growth factor overexpression ameliorates liver inflammation and fibrosis in a mouse model of nonalcoholic steatohepatitis. Hepatol Int 2012; 6: 620-630.
86. Zimmermann HW, Tacke F. Modification of chemokine pathways and immune cell infiltration as a novel therapeutic approach in liver inflammation and fibrosis. Inflamm Allergy Drug Targets 2011; 10: 509-536.
87. Stauffer JK, Scarzello AJ, Jiang Q, Wiltrout RH. Chronicinflammation, immune escape, and oncogenesis in the liver: aunique neighborhood for novel intersections. Hepatology 2012; 56: 1567-1574.
88. Park O, Jeong WI, Wang L etal. Diverse roles of invariant natural killer T cells inliver injury and fibrosis induced by carbon tetrachloride. Hepatology 2009; 49: 1683-1694.
89. Sandra MB, Flavia P, Nancy F etal. Dendritic cells regulate angiogenesis associated with liverfibrogenesis. Angiogenesis 2014; 17: 119-128.
90. Sozzani S, Rusnati M, Riboldi E. Dendritic cell-endothelial cell cross-talk in angiogenesis. Trends Immunol 2007; 28: 385-392.
91. Sugimoto H, Hamano Y, Charytan D etal. Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodiesand soluble VEGF receptor 1 (sFlt-1) induces proteinuria. J Biol Chem 2003; 278: 12605-12608.
92. Strieter RM. Cancer CXC chemokine networks andtumor angiogenesis. Eur J Cancer 2006; 42: 768-778.
93. Sozzani S. Dendritic cell trafficking: more than justchemokines. Cytokine Growth Factor Rev 2005; 16: 581-592.
94. Wang YQ, Ikeda K, Ikebe T etal. Inhibition of stellate cell proliferation and activation by the semisynthetic analogue of fumagillin TNP-470 in rats. Hepatology 2000; 32: 980-989.
95. Kin M, Torimura T, Ueno T etal. Angiogenesis inhibitor TNP-470 suppresses the progression of experimentally-induced hepatocellular carcinoma in rats. Int J Oncol 2000; 16: 375-382.
96. Yang L, Kwon J, Popov Y etal. Vascular endothelial growth factor promotes fibrosis resolution and repair in mice. Gastroenterology 2014; 146: 1339-1350.
97. Coch L, Mejias M, Berzigotti A etal. Disruption of negative feedback loop between vasohibin-1 and VEGF decreases portal pressure, angiogenesis and fibrosis in cirrhotic rats. Hepatology 2014; 60: 633-647.
98. Mejias M, Garcia-Pras E, Tiani C etal. Beneficialeffects of sorafenib on splanchnic, intrahepatic, and Porto collateral circulations in portal hypertensive and cirrhotic rats. Hepatology 2009; 49: 1245-1256.
99. Wang Y, Gao J, Zhang D etal. New insights into the antifibrotic effects of sorafenibon hepatic stellate cells and liver fibrosis. J Hepatol 2010; 53: 132-144.
100. Chor JS, Yu J, Chan KK etal. Stephania tetrandra prevents andregresses liver fibrosis induced by carbon tetrachloride in rats. J Gastroenterol Hepatol 2009; 24: 853-859.
101. Rinne ML, Lee EQ, Nayak L etal. Update on bevacizumab andother angiogenesis inhibitorsfor brain cancer. Expert Opin Emerg Drugs 2013; 18: 137-153.
102. Scharf VF, Farese JP, Coomer AR etal. Effect of bevacizumab on angiogenesis and growth of canine osteosarcoma cells xenografted in athymic mice. Am J Vet Res 2013; 74: 771-778.
103. Walker EJ, Su H, Shen F etal. Bevacizumab attenuates VEGF-induced angiogenesis and vascular malformations in the adult mouse brain. Stroke 2012; 43: 1925-1930.
104. Majumder S, Piguet AC, Dufour JF, Chatterjee S. Study of the cellular mechanism of Sunitinib mediated inactivation of activated stellate cells and its implications in angiogenesis. Eur J Pharmacol 2013; 705: 86-95.
105. Tugues S, Morales-Ruiz M, Fernandez-Varo G etal. Microarray analysis of endothelial differentially expressed genes in liver of cirrhotic rats. Gastroenterology 2005; 129: 1686-1695.
106. Sakaida I. Autologous bone marrow cell infusion therapy for liver cirrhosis-now and future. Rinsho Byori 2011; 59: 1092-1098.
107. Sakamoto M, Nakamura T, Torimura T etal. Transplantation of endothelial progenitor cells ameliorates vascular dysfunction and portal hypertension in carbon tetrachloride-induced rat liver cirrhotic model. J Gastroenterol Hepatol 2013; 28: 168-178.
108. Taniguchi E, Kin M, Torimura T etal. Endothelial progenitor cell transplantation improves the survival following liver injury in mice. Gastroenterology 2006; 130: 521-531.
109. Nakamura T, Torimura T, Iwamoto H etal. Prevention of liver fibrosis and liver reconstitution of DMN-treated rat liver by transplanted EPCs. Eur J Clin Invest 2012; 42: 717-728.
110. Zhan Y, Wei Y, Wang Y etal. Differentiation of hematopoietic stemcellsintohepatocytesin liver fibrosis in rats. Transplant Proc 2006; 38: 3082-3085.
111. Tsolaki E, Athanasiou E, Gounari E etal. Hematopoietic stem cells and liver regeneration: differentially acting hematopoietic stem cell mobilization agents reverse induced chronic liver injury. Blood Cells Mol Dis 2014; 53: 124-132.
112. Burganova GR. Effectiveness of autologous hematopoietic stem cells transplantation in patients with liver cirrhosis. Eksp Klin Gastroenterol 2012; 4: 91-97.
113. Duffield JS, Forbes SJ, Constandinou CM etal. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65.
114. Salcedo X, Medina J, Sanz-Cameno P etal. The potential of angiogenesis soluble markers in chronic hepatitis C. Hepatology 2005; 42: 696-701.
115. Liang X, Xu F, Li X etal. VEGF signal system: the application of antiangiogenesis. Curr Med Chem 2014; 21: 894-910.
116. Pircher A, Wellbrock J, Fiedler W etal. New antiangiogenic strategies beyond inhibition of vascular endothelial growth factor with special focus on axon guidance molecules. Oncology 2014; 86: 46-52.
117. Namisaki T, Yoshiji H, Noguchi R etal. The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute failure. J Angiogenes Res 2010; 2: 16.
118. Behdani M, Zeinali S, Karimipour M etal. Expression, purification, and characterization of a diabody against the most important angiogenesis cell receptor: vascular endothelial growth factor receptor 2. Adv Biomed Res 2012; 1: 34.
119. Meissner M, Doll M, Hrgovic I etal. Suppression of VEGFR2 expression in human endothelial cells by dimethylfumarate treatment: evidence for anti-angiogenic action. J Invest Dermatol 2011; 131: 1356-1364.
120. Tessneer KL, Pasula S, Cai X etal. Genetic reduction of vascular endothelial growth factor receptor 2 rescues aberrant angiogenesis caused by epsin deficiency. Arterioscler Thromb Vasc Biol 2014; 34: 331-337.
121. Kang CM, Wang DW, Ying T etal. Progress in the study of VEGFR-2 signaling pathway. Prog Biochem Biophys 2009; 36: 1267-1274.
122. Downward J. PI 3-kinase, Akt and cell survival. Semin Cell Dev Biol 2004; 15: 177-182.
123. Holmqvist K, Cross MJ, Rolny C etal. The adaptor protein shb binds to tyrosine 1175 in vascular endothelial growth factor (VEGF) receptor-2 and regulates VEGF-dependent cellular migration. J Biol Chem 2004; 279: 22267-22275.
124. Matsumoto T, Bohman S, Dixelius J etal. VEGF receptor-2 Y951 signaling and a role for the adapter molecule TSAd in tumor angiogenesis. EMBO 2005; 24: 2342-2353.
125. Novo E, Cannito S, Zamara E etal. Proangiogenic cytokines as hypoxia-dependent factors stimulating migration of human stellate cells. Am J Pathol 2007; 170: 1942-1953.
126. Taura K, De Minicis S, Seki E etal. Stellate cells secrete angiopoietin 1 that induces angiogenesis in liver fibrosis. Gastroenterology 2008; 135: 1729-1738.
127. Sun XJ, Zhang YY. Main signal pathway of angiogenesis. J Int Oncol 2010; 37: 95-98.
128. Benedito R, Hellström M. Notch as a hub for signaling in angiogenesis. Exp Cell Res 2013; 319: 1281-1288.
129. Gao W, Sweeney C, Walsh C etal. Notch signaling pathways mediate synovial angiogenesis in response to vascular endothelial growth factor and angiopoietin 2. Ann Rheum Dis 2013; 72: 1080-1088.
130. Thomas JL, Baker K, Han J etal. Interactions between VEGFR and Notch signaling pathways in endothelial and neural cells. Cell Mol Life Sci 2013; 70: 1779-1792.
131. Li JL, Harris AL. Crosstalk of VEGF and Notch pathways in tumor angiogenesis: therapeutic implications. Front Biosci 2009; 14: 3094-3110.
132. Tu J, Li Y, Hu Z. Notch1 and 4 signaling responds to an increasing vascular wall shear stress in a rat model of arteriovenous malformations. Biomed Res Int 2014; 2014: 368082.
133. Liu Z, Fan F, Wang A, Zheng S, Lu Y. Dll4-Notch signaling in regulation of tumor angiogenesis. J Cancer Res Clin Oncol 2014; 140: 525-536.
134. Nijjar SS, Wallace L, Crosby HA etal. Altered Notch ligand expression in human liver disease: further evidence for a role of the Notch signaling pathway in neovascularization and biliary ductular defects. Am J Pathol 2002; 160: 1695-1703.
135. Köhler C, Bell AW, Bowen WC etal. Expression of Notch-1 and its ligand Jagged-1 in rat liver during liver regeneration. Hepatology 2004; 39: 1056-1065.
136. Sayin O, Tokgöz Y, Arslan N. Investigation of adropin and leptin levels in pediatric obesity-related nonalcoholic fatty liver disease. J Pediatr Endocrinol Metab 2014; 27: 1-6.
137. Aleffi S, Petrai I, Bertolani C etal. Upregulation of proinflammatory and proangiogenic cytokines by leptin in human stellate cells. Hepatology 2005; 42: 1339-1348.
138. Korah TE, El-Sayed S, Elshafie MK etal. Significance of serum leptin and adiponectin levels in Egyptian patients with chronic hepatitis C virus associated steatosis and fibrosis. World J Hepatol 2013; 5: 74-81.
139. Safar Zadeh E, Lungu AO, Cochran EK etal. the liver diseases of lipodystrophy: the long-term effect of leptin treatment. J Hepatol 2013; 59: 131-137.
140. Chen L, Shi Y, Jiang CY etal. Expression of leptin and leptin receptor in hepatocellular carcinoma and the clinicopathological significance. Nan Fang Yi Ke Da Xue Xue Bao 2011; 31: 830-833.
141. Ye J. Regulation of leptin by hypoxia. J Appl Physiol 2008; 105: 1687-1690.
142. Choi SS, Syn WK, Karaca GF etal. Leptin promotes the myofibroblastic phenotype in stellate cells by activating the hedgehog pathway. J Biol Chem 2010; 285: 36551-36560.
143. Choi SS, Omenetti A, Witek RP etal. Hedgehog pathway activation and epithelial-to-mesenchymal transitions during myofibroblastic transformation of rat cells in culture and cirrhosis. Am J Physiol Gastrointest Liver Physiol 2009; 297: G1093-1106.
144. Witek RP, Yang L, Liu R etal. Liver cell-derived microparticles activate hedgehog signaling and alter gene expression in endothelial cells. Gastroenterology 2009; 136: 320-330.
145. Cales P, Boursier J, Chaigneau J etal. Treatment of liver fibrosis: clinical aspects. Gastroenterol Clin Biol 2009; 33: 958-966.
146. Pinzani M, Reboots K. Liver fibrosis: from the bench to clinical targets. Dig Liver Dis 2004; 36: 231-242.
147. Ferrara N. Pathways mediating VEGF-independent tumor angiogenesis. Cytokine Growth Factor Rev 2010; 21: 21-26.